SEC Form 4 · accession 0001179110-18-005506
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Trachtenberg
Officer — General Counsel and Secretary
Period of report
Apr 5, 2018
Accepted (ET)
Apr 9, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.62 | Apr 5, 2018 | A | 150,000 | A | — | Apr 4, 2028 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1This option was granted on April 5, 2018 and vests over four years beginning on the vesting commencement date of April 2, 2018, with 25% of the shares underlying the option vesting on April 2, 2019, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.